Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

Visit https://www.peervoice.com/CAX860 to view the entire programme with slides. After completing “Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome”, participants will be able to: Describe the pathophysiology of atypical hemolytic uremic syndrome (aHUS), including the involvement of terminal complement dysregulation and how this impacts renal function; Assess the clinical significance of clinical trial data and real-world evidence evaluating the use of complement component C5 inhibitors in managing aHUS; Implement evidence-based best practices for the timely recognition and diagnosis of aHUS in patients who present with symptoms of this condition; and Formulate appropriate, individualized approaches to managing aHUS in patients presenting for first-line treatment or experiencing relapse after treatment discontinuation.